Structure and Processes of Existing Practice in Radiotherapy Peer Review: A Systematic Review of the Literature.

Peer review in radiotherapy is an essential step in clinical quality assurance to avoid planning-related errors that can impact on patient safety and treatment outcomes. Despite recommendations that radiotherapy centres should include peer review in their regular quality assurance pathway, adoption of the practice has not been universal, and to date there have been no formal guidelines set out to standardise the process. We undertook a systematic review of the literature to determine existing practice in radiotherapy peer review internationally, with respect to meeting structure and processes, in order to define a standardised framework. A PubMed and Web of Science search identified 17 articles detailing peer review practice. The results revealed significant variation in peer review processes between institutions, and a lack of consensus on documentation and reporting. Variations in the grading of outcomes of peer review were also noted. Taking into account the results of this review, a framework for standardising the process and outcome documentation for peer review has been developed. This can be utilised by radiotherapy centres introducing or updating peer review practice, and can facilitate meaningful evaluation of the clinical impact of peer review in the future.

MRIgRT head and neck anthropomorphic QA phantom: Design, development, reproducibility, and feasibility study.

PURPOSE: The purpose of this paper was to design, manufacture, and evaluate a tissue equivalent, dual magnetic resonance/computed tomography (MR/CT) visible anthropomorphic head and neck (H&N) phantom. This phantom was specially designed as an end-to-end quality assurance (QA) tool for MR imaging guided radiotherapy (MRIgRT) systems participating in NCI-sponsored clinical trials. METHOD: The MRIgRT H&N phantom was constructed using a water-fillable acrylic shell and a custom insert that mimics an organ at risk (OAR) and target structures. The insert consists of a primary and secondary planning target volume (PTV) manufactured of a synthetic Clear Ballistic gel, an acrylic OAR and surrounding tissue fabricated using melted Superflab. Radiochromic EBT3 film and thermoluminescent detectors (TLDs) were used to measure the dose distribution and absolute dose, respectively. The phantom was evaluated by conducting an end-to-end test that included: imaging on a GE Lightspeed CT simulator, planning on Monaco treatment planning software (TPS), verifying treatment setup with MR, and irradiating on Elekta's 1.5 T Unity MR linac system. The phantom was irradiated three times using the same plan to determine reproducibility. Three institutions, equipped with either ViewRay MRIdian 60 Co or ViewRay MRIdian Linac, were used to conduct a feasibility study by performing independent end-to-end studies. Thermoluminescent detectors were evaluated in both reproducibility and feasibility studies by comparing ratios of measured TLD to reported TPS calculated values. Radiochromic film was used to compare measured planar dose distributions to expected TPS distributions. Film was evaluated by using an in-house gamma analysis software to measure the discrepancies between film and TPS. RESULTS: The MRIgRT H&N phantom on the Unity system resulted in reproducible TLD doses (SD < 1.5%). The measured TLD to calculated dose ratios for the Unity system ranged from 0.94 to 0.98. The Viewray dose result comparisons had a larger range (0.95-1.03) but these depended on the TPS dose calculations from each site. Using a 7%/4 mm gamma analysis, Viewray institutions had average axial and sagittal passing rates of 97.3% and 96.2% and the Unity system had average passing rates of 97.8% and 89.7%, respectively. All of the results were within the Imaging and Radiation Oncology Core in Houston (IROC-Houston) standard credentialing criteria of 7% on TLDs, and >85% of pixels passing gamma analysis using 7%/4 mm on films. CONCLUSIONS: An MRIgRT H&N phantom that is tissue equivalent and visible on both CT and MR was developed. The results from initial reproducibility and feasibility testing of the MRIgRT H&N phantom using the tested MGIgRT systems suggests the phantom's potential utility as a credentialing tool for NCI-clinical trials.

MRIgRT dynamic lung motion thorax anthropomorphic QA phantom: Design, development, reproducibility, and feasibility study.

PURPOSE: To design, manufacture, and evaluate a dynamic magnetic resonance imaging/computed tomography (MRI/CT)-compatible anthropomorphic thorax phantom used to credential MR image-guided radiotherapy (MRIgRT) systems participating in NCI-sponsored clinical trials. METHOD: The dynamic anthropomorphic thorax phantom was constructed from a water-fillable acrylic shell that contained several internal structures representing radiation-sensitive organs within the thoracic region. A custom MR/CT visible cylindrical insert was designed to simulate the left lung with a centrally located tumor target. The surrounding lung tissue was constructed from a heterogeneous in-house mixture using petroleum jelly and miniature (2-4 mm diameter) styrofoam balls and the tumor structure was manufactured from liquid PVC plastic. An MR conditional pneumatic system was developed to allow the MRIgRT insert to move in similar inhale/exhale motions. TLDs and radiochromic EBT3 film were inserted into the phantom to measure absolute point doses and dose distributions, respectively. The dynamic MRIgRT thorax phantom was evaluated through a reproducibility study and a feasibility study. Comprehensive end-to-end examinations were done where the phantom was imaged on a CT, an IMRT treatment plan was created and an MR image was captured to verify treatment setup. Then, the phantom was treated on an MRIgRT system. The reproducibility study evaluated how well the phantom could be reproduced in an MRIgRT system by irradiating three times on an Elekta's 1.5 T Unity system. The phantom was shipped to three independent institutions and was irradiated on either an MRIdian cobalt-60 (60 Co) or an MRIdian linear accelerator system. Treatment evaluations used TLDs and radiochromic film to compare the planned treatment reported on the treatment planning software against the measured dose on the dosimeters. RESULTS: The phantom on the Unity system had reproducible TLD doses measurements (SD < 1.5%). The measured TLD to calculated dose ratios from the reproducibility and feasibility studies ranged from 0.93 to 1.01 and 0.96 to 1.03, respectively. Using a 7%/5 mm gamma analysis criteria, the reproducibility and feasibility studies resulted in an average passing rate of 93.3% and 96.8%, respectively. No difference was noted in the results between the MRIdian 60 Co and MRIdian 6 MV linac delivery to the phantom and all treatment evaluations were within IROC-Houston's acceptable criterion. CONCLUSIONS: A dosimetrically tissue equivalent, CT/MR visible, motion-enabled anthropomorphic MRIgRT thorax phantom was constructed to simulate a lung cancer patient and was evaluated as an appropriate NIH credentialing tool used for MRIgRT systems.

Investigation of TLD and EBT3 performance under the presence of 1.5T, 0.35T, and 0T magnetic field strengths in MR/CT visible materials.

PURPOSE: The aim of this study was to investigate thermoluminescent dosimeters (TLD) and radiochromic EBT3 film inside MR/CT visible geometric head and thorax phantoms in the presence of: 0, 0.35, and 1.5 T magnetic fields. METHODS: Thermoluminescent Dosimeters reproducibility studies were examined by irradiating IROC-Houston's TLD acrylic block five times under 0 and 1.5 T configurations of Elekta's Unity system and three times under 0 and 0.35 T configurations of ViewRay's MRIdian Cobalt-60 (60 Co) system. Both systems were irradiated with an equivalent 10 × 10 cm2 field size, and a prescribed dose of 3 Gy to the maximum depth deposition (dmax). EBT3 film and TLDs were investigated using two geometrical Magnetic Resonance (MR)-guided Radiation Therapy (MRgRT) head and thorax phantoms. Each geometrical phantom had eight quadrants that combined to create a centrally located rectangular tumor (3 × 3 × 5 cm3 ) surrounded by tissue to form a 15 × 15 × 15 cm3 cubic phantom. Liquid polyvinyl chloride plastic and Superflab were used to simulate the tumor and surrounding tissue in the head phantom, respectively. Synthetic ballistic gel and a heterogeneous in-house mixture were used to construct the tumor and surrounding tissue in the thorax phantom, respectively. EBT3 and double-loaded TLDs were used in the phantoms to compare beam profiles and point dose measurements with and without magnetic fields. GEANT4 Monte Carlo simulations were performed to validate the detectors for both Unity 0 T/1.5 T and MRIdian 0 T/0.35 T configurations. RESULTS: Average TLD block measurements which, compared the magnetic field effects (magnetic field vs 0 T) on the Unity and MRIdian systems, were 0.5% and 0.6%, respectively. The average ratios between magnetic field effects for the geometric thorax and head phantoms under the Unity system were -0.2% and 1.6% and for the MRIdian system were 0.2% and -0.3%, respectively. Beam profiles generated with both systems agreed with Monte Carlo measurements and previous literature findings. CONCLUSIONS: TLDs and EBT3 film dosimeters could potentially be used in MR/CT visible tissue equivalent phantoms that will experience a magnetic field environment.

Innovations in Radiotherapy Technology.

Many low- and middle-income countries, together with remote and low socioeconomic populations within high-income countries, lack the resources and services to deal with cancer. The challenges in upgrading or introducing the necessary services are enormous, from screening and diagnosis to radiotherapy planning/treatment and quality assurance. There are severe shortages not only in equipment, but also in the capacity to train, recruit and retain staff as well as in their ongoing professional development via effective international peer-review and collaboration. Here we describe some examples of emerging technology innovations based on real-time software and cloud-based capabilities that have the potential to redress some of these areas. These include: (i) automatic treatment planning to reduce physics staffing shortages, (ii) real-time image-guided adaptive radiotherapy technologies, (iii) fixed-beam radiotherapy treatment units that use patient (rather than gantry) rotation to reduce infrastructure costs and staff-to-patient ratios, (iv) cloud-based infrastructure programmes to facilitate international collaboration and quality assurance and (v) high dose rate mobile cobalt brachytherapy techniques for intraoperative radiotherapy.

SU-E-J-154: Advantages of Treating Thoracic Cancer Patients in an Upright Position.

PURPOSE: To compare lung volume and respiratory motion in supine and upright positions to assess the potential advantages of treating thoracic cancer patients in an upright position. METHODS: A multi-position MRI scanner (FONAR, Melville, NY) was used to take MRI images of 4 healthy volunteers in both supine and upright setup positions (expected total accrual: 15 volunteers). In each case, a volumetric scan was acquired during breath-hold at end of normal expiration, followed by a series of sagittal cine MR scans taken during normal respiration. The exhale volume images were imported into a treatment planning system and lung volumes were delineated and compared for different setup positions. The trajectory of points inside the lung were tracked in the cine images and analyzed using a deformable image registration technique and a principal component analysis (PCA) model. RESULTS: The average exhale lung volume was 38% (894cc) larger (range: 23%-57%, 570-121 1cc) when volunteers were in the upright position compared with the supine position. The amplitude of motion for a set of landmark points in the lung volume ranged from 〈2mm (distant from the diaphragm) to 29 mm (close to the diaphragm) in the superior-inferior direction. A linear fit to the amplitude of respiratory motion vs. distance from the diaphragm for all 4 volunteers indicated no difference on averagein the range of motion for the two setup positions, but there was variability between individuals. CONCLUSIONS: While the magnitude of motion was similar, the absolute lung volumes were much larger in the upright position than in the supine position, which suggests that treating thoracic patients in the upright position may allow for a reduction in the mean lung dose. The study was partially supported by a sponsored research grant from Varian Medical Systems.

SU-E-J-186: CT Textures Can be Predictive for Tumor Shrinkage.

PURPOSE: To determine if NSCLC GTV CT textures can be predictive for tumor shrinkage after proton therapy with concurrent chemotherapy. METHODS: Simulation and weekly 4DCTs were obtained from 25 patients with locally advanced NSCLC treated by proton therapy at a 74 Gy dose level with concurrent chemotherapy. In-house deformable image registration software based on the demons algorithm propagated the physician-generated planning GTV onto each weekly image set. GTV soft tissue volumes were then extracted from CT images by in-house software which pruned out voxels below a cutoff HU threshold. Patients whose normalized end-treatment pruned GTV was less than the group median were classified as 'strong responders.'The remaining patients were classified as 'weak responders.' For each pruned GTV, the MaZda texture analysis software generated quantitative 3D texture features based on the image histogram, absolute gradient, co-occurrence matrix, and run-length matrix. Using the Fisher coefficient, a subset of these texture features that were relevant to distinguishing the two response groups was obtained. In-house software and MaZda were then used to perform neural network data classification with leave-one-out cross-validation based on this texture feature subset. The true positive rate (TPR), false positive rate (FPR), classification accuracy, and one-sided p-values were recorded. RESULTS: Six classification models were tested. Each model had a unique combination of feature extraction and analysis parameters. Taking 'strong responders' to be the 'positive' class, the average TPR was 0.66 (0.60 - 0.75), the average FPR was 0.36 (0.31 - 0.40), the average classification accuracy was 64.8% (60.0% - 68.0%), and the average one-sided p-value was 0.118 (0.055 - 0.215). CONCLUSIONS: There is some evidence showing that NSCLC GTV CT textures can be predictive for tumor shrinkage after proton therapy. Further work should be done to include more patients, texture metrics, and data analysis techniques. The presenting author receives funding support from a Hertz Foundation Applied Science Fellowship.

WE-E-213CD-09: Multi-Atlas Fusion Using a Tissue Appearance Model.

PURPOSE: To improve multi-atlas based auto-segmentation by integrating a tissue appearance model with the Simultaneous Truth and Performance Level Estimation (STAPLE) algorithm to perform multi-atlas fusion. METHODS: Ten head-and-neck planning CT images were acquired (resolution: 1.0×1.0×2.5mm3 ) and the parotid glands were contoured manually by a head-and-neck oncologist. We performed 10 leave-one-out tests by using one patient as test patient and the rest of 9 patients as atlases. Deformable registration was first applied to transform the atlas parotid contours to the test image one by one. The STAPLE algorithm was initialized by a parotid tissue appearance model, which was estimated from the test image and encoded the intensity information of parotid glands. The individual deformed contours were then fused using the STAPLE algorithm to produce a best approximation of the true contour. The tissue appearance model was also applied to a deformable model segmentation to further refine the fused contours. RESULTS: The multi-atlas fusion using the tissue appearance model produced an average Dice coefficient of 85.2%±3.1% (left parotid) and 84.9%±3.9% (right parotid) over the 10 tests between the auto-contour and the manual contour, and an average mean surface distance of 1.6±0.3mm and 1.6±0.4mm for left and right parotids respectively. This demonstrated a good agreement between the manual contours and the auto- delineated contours. Our results also showed that, without using the tissue appearance model, the auto-delineated parotid contours might include nearby bony structures; however, using the appearance model was able to correct this problem. CONCLUSIONS: Including the intensity information using a tissue appearance model into STAPLE algorithm for multi-atlas fusion showed improvement in refining the anatomical boundaries in the multi- atlas based auto-segmentation.

SU-E-T-575: To Analyze the Clinical Impact of Esophageal Sparing on Treatment Plans for Patients with Grade 3 Esophagitis.

PURPOSE: To analyze the clinical impact of esophageal sparing on treatment plans for patients with grade 3 esophagitis. METHODS: The treatment plans of 8 patients (project total: 20 patients) who were treated with IMRT and exhibited stage 3 esophagitis were re-planned to give a simulated clinical plan with dose distribution that mirrored our current clinical practice (74Gy to the target, and 5mm margins), and a plan that emphasized esophageal sparing. Doses to the esophagus, heart, cord, lung and PTV were compared. RESULTS: Comparing the esophageal sparing plan to the simulated clinical plan, the mean reduction in esophageal volume receiving 50, 55, 60, 65, and 70Gy were 2.0, 3.2, 5.0, 7.2, and 10.9 cm3 , respectively. The mean reduction in the continuous length of esophagus receiving 50, 55, 60, 65, and 70Gy were 12, 24, 38, 40, and 47mm, respectively. The associated reduction in dose to 90% and 95% of the PTV was 2.2 and 3.8Gy, respectively. Of the 8 patients examined, 2 showed a significant decrease in PTV coverage (4.6Gy, 12.3Gy for 90% of PTV), 4 showed decreases under 1.1Gy, but 2 showed an increase of 1.4Gy and 0.5Gy for 90% PTV. Cord dose was maintained below 50Gy, and there was a slight increase in mean heart dose and mean lung dose of 2.4Gy, and 2.7Gy, respectively. Data will also be presented comparing these plans with the actual treated plans (for which the patients had grade 3 esophagitis) and plans that emphasize PTV coverage. CONCLUSIONS: Treatment planning to emphasize esophageal sparing can reduce the volume and continuous length of the esophagus which receives high doses. There is some associated modest reduction in PTV coverage. In summary, in many cases esophageal sparing can be accomplished for lung cancer cases while maintaining adequate PTV coverage, although there is variability between patients.

SU-E-T-560: Inter- and Intra-Fraction Variations in Esophageal Dose for Lung Cancer Patients, and the Impact of Setup Technique and Treatment Modality.

PURPOSE: To understand the dose-response of the esophagus in photon and proton therapy, it is important to appreciate the variations in delivered dose caused by inter- and intra-fraction motion. METHODS: Four lung cancer patients were identified who had experienced grade 3 esophagitis during their treatment, and for whom their esophagus was close, but not encompassed by, the treatment volume. Each patient had been treated with proton therapy using 35-37 2Gy fractions, and had received weekly 4DCT imaging. IMRT plans were also created using the same treatment planning constraints. In-house image registration software was used to deform the esophagus contour from the treatment plan to each phase of the 4DCT for each weekly image set. Daily setup using both bony and soft tissue (GTV) registration was simulated, and the treatment dose calculated for each CT image. Changes to the esophagus DVH relative to the treatment plan were quantified in terms of the relative volume of the esophagus receiving 45, 55, and 65Gy (V45, V55 and V65). RESULTS: For all combinations of treatment modality (photon, proton) and setup method (bony, GTV), intra-fraction motion resulted in a range of V45, V55 and V65 from 3.6 to 5.5%. Inter-fraction motion comparing daily exhale or inhale phases showed the range of V45, V55 and V65 from 8.5 to 18.6% (exhale) and 9.8 to 16.3% (inhale). CONCLUSIONS: Inter-fractional motion resulted in larger variations in dose delivered to the esophagus than intra-fractional motion. The inter-fraction range for V45, V55 and V65 varied by around 10% between patients. The treatment modality (photon, proton) and setup technique (bony, GTV) had minimal impact on the results.

SU-E-T-86: Development and Implementation of the Use of Optically Stimulated Luminescent Detectors in the Radiological Physics Center Anthropomorphic Quality Assurance Phantoms.

PURPOSE: To study the angular dependence of optically stimulated luminescence dosimeters (OSLD) in the Radiological Physics Center anthropomorphic quality assurance pelvic phantom to provide accurate dosimetric measurements as a replacement for TLD. METHODS: A spherical phantom was constructed to investigate the angular response of the OSLD as oriented in the RPC pelvic phantom. Three OSLD per irradiation angle, placed at the center of the spherical phantom, were irradiated with 100 cGy from six different angles. The angular response at each angle was determined relative to the OSLD response when the beam was incident normally on the OSLD surface. A pelvic phantom dosimetry insert was modified to include both TLD and OSLD. Three treatment plans were developed in Pinnacle v9.0 and one in Accuray's Multiplan, each with increasing angular beam delivery (4 field, IMRT, SmartArc, CyberKnife) for the pelvic phantom using a common dose prescription and constraints. Each plan was delivered to the phantom three times, containing two TLD and two OSLD, oriented in the transverse plane, at the center of the PTV. The dose delivered to the TLD and OSLD was calculated for each treatment and then compared. RESULTS: The angular dependence correction factor for the spherical phantom was found to be uniformly 1.041 ± 0.003 from single beam edge-on irradiations. The angular dependence correction in the pelvic phantom from multiple beam orientation irradiations was 1.024 ± 0.002, such that the OSLD dose agreed with the TLD dose. Applying the OSLD pelvic phantom correction factor, the RPC measured dose to planning system calculated dose ratio was 0.995 ± 0.009. The established RPC phantom TLD dose to calculated dose ratio was 0.995 ± 0.010. CONCLUSIONS: An anthropomorphic phantom OSLD angular dependence correction factor was established such that the final OSLD dose measurements agreed with RPC's TLD dose measurements to within 1%. Work supported by grant CA 10953, awarded by NCI, DHHS.

SU-E-T-394: Comparison of Planned Dose Distribution Vs. Delivered Dose Distribution for Both IMRT and Proton Therapy Using Weekly Repeat 4DCT Data Sets.

PURPOSE: To evaluate treatment deviations and the impact of treatment modality in the presence of breathing motion and anatomical changes during the course of lung cancer radiotherapy. METHODS: Two non-small cell lung cancer patients were enrolled in a randomized clinical trial to compare IMRT and proton therapy. To rigorously evaluate the impact of motion and anatomical changes, we used a '5D' dose accumulation approach to sum dose distributions from phase-to-phase and week-to-week to the reference (end-expiration) phase of the original planning 4DCT data set. Six to eight weekly 4DCT data sets that consisted of 10 breathing phases were acquired during the treatment course. The original plan was re-calculated for each phase and deformably mapped to the reference phase to compare the 'delivered' dose distribution with the planned dose distribution of both the IMRT plan and the proton plan for each patient. DVHs derived from delivered dose distribution were compared to that from the planned dose distribution. RESULTS: The delivered dose showed 3% and 2% increase in the dose to the CTV for IMRT and proton plan respectively. Target coverage remained acceptable despite tumor shrinkage from 29% to 49%. The doses to normal structures, such as lung and heart, increased more in the proton plan than in the IMRT plan. The V20 of the total lung volume increased by 4% and 6% from the delivered dose compared to the planned dose for IMRT and proton plan, respectively. CONCLUSIONS: The results showed sufficient target coverage was maintained for both modalities. Increases in lung dose were observed in both modalities, but more in the proton arm, perhaps due to weight loss and tumor shrinkage. Adaptive proton therapy strategy is recommended to minimize normal tissue doses. Supported in part by NCI P01 CA021239-29A1.

SU-E-T-250: Dose-Response Curves for the Esophagus.

PURPOSE: To determine the dose-response curve for the esophagus, using esophageal thickening as a surrogate for radiation injury. METHODS: 15 esophageal cancer patients were selected who had received weekly 4DCT images throughout their course of concurrent chemo-radiotherapy (IMRT) to a total of 50.4Gy. Each patient had a length of at least 4cm of esophagus that was outside the GTV but received the full prescription dose. The weekly CT images were registered with the original treatment planning CT images using deformable registration techniques, and the esophagus contours mapped to the weekly images. The relative change in esophagus size was calculated as the average ratio of the cross-sectional area of the esophagus (minus air) in the weekly images to the area in the planning images for a 1cm long region of the esophagus in the center of the CTV (i.e. away from the GTV and field edge). We are considering this region to be 'normal esophagus.' RESULTS: Thirteen of the 15 patients experienced mild esophagitis. The average relative expansion increased as the treatment progressed. For all patients the esophagus was thicker at the final week of treatment than its pre-treatment size. For 7/15 patients the esophageal expansion was larger than 1.3. The average relative expansion of the esophagus was 1.30±0.19 (range: 1.04 - 1.67). We will present dose-response curves calculated from the weekly 4DCTs. CONCLUSIONS: The esophagus expands in response to radiation, reaching approximately a 30% increase in cross-sectional area during the final week of a 50.4Gy treatment, although there is much variability between patients.

SU-F-BRCD-05: Mean Regional Dose to the Esophagus Predicts Acute Toxicity Rate for Lung Cancer Patients.

PURPOSE: The relationship between spatial aspects of the dose distribution and incidence of acute radiation esophagitis for non-small-cell lung cancer (NSCLC) patients is not well understood. Specifically, the location of dose along the superior-inferior (SI) axis of the esophagus has not been previously considered. We introduce the concept of mean regional dose (MRD) calculated for esophageal subvolumes, and test for significance for prediction of acute esophagitis (AE). METHODS: The 3D dose distribution within the esophagus was extracted for 541 NSCLC patients treated with definitive photon therapy. The esophagus contour was divided into equal geometric halves, thirds, and fourths along the SI direction of the structure. MRD in each subvolume was calculated. Univariate logistic regression was performed to determine the correlation between MRD and CTCAE3.0 AE grade = 2 (medical intervention). The MRD was incorporated into an existing NTCP model (based on mean dose for the total esophageal volume) as a separate additive factor. RESULTS: Univariate analysis indicated a significant correlation between AE grade = 2 and MRD in each of the esophageal subvolumes except for the inferior third and inferior-most quarter. There was a statistically significant improvement when including the additive MRD factor for the superior/inferior halves, superior/inferior thirds, and superior-most/inferior-most quarters into the NTCP model. CONCLUSIONS: This study investigates previously unexplored regional differences in delivered dose to the esophagus of patients treated for NSCLC. There is evidence to suggest that dose to the superior portions of the esophagus is more important as it relates to the potential for acute toxicity. The 541 patient cohort is the largest database used to investigate AE in patients treated for NSCLC, strengthening the power of the statistical results. Additional methods to incorporate dose in individual esophagus voxels (along the SI axis) into the NTCP model are also being explored.

SU-E-T-184: LINAC Commissioning Measurements Utilizing the Cylindrical Arc Check Phantom.

PURPOSE: New devices for IMRT and VMAT QA are continually becoming available. Despite the availability of these devices they are underutilized for routine mechanical QA. In this work we take advantage of the cylindrical geometry of the Arc Check phantom to perform tests that are an integral part of commissioning and routine QA. METHODS: The Arc Check is a cylindrical phantom with a diameter of 26.59cm and a 1386 diode array arranged on a cylindrical plane. Owing to its cylindrical design it is capable of measuring entry and exit radiation. For this experiment the Arc Check was set up using the mechanical pointer at 86.7cm SSD. The device was leveled using its inclinometer and was properly rotated to align with the lasers and cross-hair. With the phantom set up at the expected isocenter of the LINAC, 100MUs with a 10×10 field were delivered at different gantry angles, couch and collimator rotations. Each delivery was recorded individually and for each one the radiation center at the entry and exit levels of the detector were estimated. That provided the path of the radiation center through the device. The radiation path was reconstructed for each rotation individually and the coincidence of the mechanical and radiation isocenter was evaluated. RESULTS: A procedure and MATLAB routine were developed that accepted as input the text files that are the output of the Arc Check measurement and geometrically reconstructed in 3-dimensions the isocenter and radiation central axis for each rotation. The coincidence of the radiation and mechanical isocenter was verified. CONCLUSIONS: This work demonstrates that by utilizing the geometry of a commercially available device multiple mechanical LINAC tests that are part of routine QA can be evaluated in one single setup.

MO-D-BRB-05: An Analysis of 13,000 Patient-Specific IMRT QA Results from 13 Different Clinical Treatment Services.

PURPOSE: To review an institution's patient-specific IMRT quality assurance (QA) results, including absolute dose and gamma analysis measurements. METHODS: Patient-specific IMRT QA records were reviewed to obtain information on absolute dose difference (ion chamber measurement; ±3% agreement criteria) and percentage of pixels passing gamma (film measurement; 5%/3 mm agreement criteria) from 2005 to 2011. The 13,002 plans reviewed, were classified by treatment service: breast (n=67), central nervous system (n =1383), gastrointestinal (n=803), genitourinary (n=1831), gynecology (n=935), hematology (n=380), head and neck (n=3697), intensity-modulated stereotactic spine radiation therapy (n=341), melanoma (n=54), mesothelioma (n=52), pediatric (n=307), sarcoma (n=201), and thoracic (n=2951). All records were analyzed for trends according to measurement date and treatment service. Plans failing to meet QA criteria were further evaluated for subsequent measured data. RESULTS: Mean difference (± one standard deviation) between the measured and calculated doses was -0.29% ± 1.64% (with the calculated values being slightly higher). The mean percentage of pixels passing gamma was 97.7% (lower 95th percentile, 92.2%). The plan pass rates were 97.7% and 99.3% for absolute dose and gamma, respectively. We observed statistically significant differences (p < 0.05) in both absolute dose and gamma measurements as a function of treatment service (particularly for stereotactic spine and mesothelioma services) and measurement date (average agreement improved with time). However, despite improved agreement between measured and calculated doses, the percentage of treatment plans failing to meet the passing criteria has remained largely constant at ∼2.3%. CONCLUSIONS: Our retrospective review of 13,002 patient-specific IMRT QA plans demonstrated that plans continue to fail IMRT QA criteria at a consistent rate. This rate serves as a clinical reference for expected rates of QA plan pass and failure for a variety of treatment services.

SU-E-T-558: Assessing the Effect of Inter-Fractional Motion in Esophageal Sparing Plans.

PURPOSE: To compare esophageal dose distributions in esophageal sparing IMRT plans with predicted dose distributions which include the effect of inter-fraction motion. METHODS: Seven lung cancer patients were used, each with a standard and an esophageal sparing plan (74Gy, 2Gy fractions). The average max dose to esophagus was 8351cGy and 7758cGy for the standard and sparing plans, respectively. The average length of esophagus for which the total circumference was treated above 60Gy (LETT60) was 9.4cm in the standard plans and 5.8cm in the sparing plans. In order to simulate inter-fractional motion, a three-dimensional rigid shift was applied to the calculated dose field. A simulated course of treatment consisted of a single systematic shift applied throughout the treatment as well a random shift for each of the 37 fractions. Both systematic and random shifts were generated from Gaussian distributions of 3mm and 5mm standard deviation. Each treatment course was simulated 1000 times to obtain an expected distribution of the delivered dose. RESULTS: Simulated treatment dose received by the esophagus was less than dose seen in the treatment plan. The average reduction in maximum esophageal dose for the standard plans was 234cGy and 386cGY for the 3mm and 5mm Gaussian distributions, respectively. The average reduction in LETT60 was 0.6cm and 1.7cm, for the 3mm and 5mm distributions respectively. For the esophageal sparing plans, the average reduction in maximum esophageal dose was 94cGy and 202cGy for 3mm and 5mm Gaussian distributions, respectively. The average change in LETT60 for the esophageal sparing plans was smaller, at 0.1cm (increase) and 0.6cm (reduction), for the 3mm and 5mm distributions, respectively. CONCLUSIONS: Interfraction motion consistently reduced the maximum doses to the esophagus for both standard and esophageal sparing plans.

EPID-guided 3D dose verification of lung SBRT.

PURPOSE: To investigate the feasibility of utilizing tumor tracks from electronic portal imaging device (EPID) images taken during treatment to verify the delivered dose. METHODS: The proposed method is based on a computation of the delivered fluence by utilizing the planned fluence and the tumor motion track for each field. A phantom study was designed to assess the feasibility of the method. The CIRS dynamic thorax phantom was utilized with a realistic soft resin tumor, modeled after a real patient tumor. The dose calculated with the proposed method was compared to direct measurements taken with 15 metal oxide semiconductor field effect transistors (MOSFETs) inserted in small fissures made in the tumor model. The phantom was irradiated with the tumor static and moved with different range of motions and setup errors. EPID images were recorded throughout all deliveries and the tumor model was tracked post-treatment with in-house developed software. The planned fluence for each field was convolved with the tumor motion tracks to obtain the delivered fluence. Utilizing the delivered fluence from each field, the delivered dose was calculated. The estimated delivered dose was compared to the dose directly measured with the MOSFETs. The feasibility of the proposed method was also demonstrated on a real lung cancer patient, treated with stereotactic body radiotherapy. RESULTS: The calculation of delivered dose with the delivered fluence method was in good agreement with the MOSFET measurements, with average differences ranging from 0.8% to 8.3% depending on the proximity of a dose gradient. For the patient treatment, the planned and delivered dose volume histograms were compared and verified the overall good coverage of the target volume. CONCLUSIONS: The delivered fluence method was applied successfully on phantom and clinical data and its accuracy was evaluated. Verifying each treatment fraction may enable correction strategies that can be applied during the course of treatment to ensure the desired dose coverage.

A multi-region algorithm for markerless beam's-eye view lung tumor tracking.

Methods that allow online lung tumor tracking during radiotherapy are desirable for a variety of applications that have the potential to vastly improve treatment accuracy, dose conformity and sparing of healthy tissue. Several publications have proposed the use of an on-board kV x-ray imager to assess the tumor location during treatment. However, there is some concern that this strategy may expose the patient to a significant amount of additional dose over the course of a typical radiotherapy treatment. In this paper we present an algorithm that utilizes the on-board portal imager of the treatment machine to track lung tumors. This does not expose the patient to additional dose, but is somewhat more challenging as the quality of portal images is inferior when compared to kV x-ray images. To quantify the performance of the proposed algorithm we retrospectively applied it to portal image sequences retrieved from a dynamic chest phantom study and an SBRT treatment performed at our institution. The results were compared to manual tracking by an expert. For the phantom data the tracking error was found to be smaller than 1 mm and for the patient data smaller than 2 mm, which was in the same range as the uncertainty of the gold standard.